PremiumThe FlyEdwards Lifesciences price target raised to $83 from $80 at Piper Sandler Edwards Lifesciences Expands Employee Stock Purchase Plans Balanced Outlook on Edwards Lifesciences: Navigating FDA Approval and Capacity Constraints PremiumRatingsHold Rating on Edwards Lifesciences: Balancing Positive Trends with TAVR Uncertainties Texas Instruments, Mondelez downgraded: Wall Street’s top analyst calls Edwards Lifesciences price target raised to $75 from $72 at Baird PremiumThe FlyEdwards Lifesciences reaffirms FY25 adjusted EPS $2.40-$2.50, consensus $2.45 Edwards Lifesciences reports Q1 EPS 61c, consensus 60c Notable companies reporting after market close 
